Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. [electronic resource]
Producer: 20200508Description: 33-40 p. digitalISSN:- 1879-0852
- Adult
- Aged
- Anilides -- therapeutic use
- Antineoplastic Agents, Immunological
- Axitinib -- therapeutic use
- Carcinoma, Renal Cell -- drug therapy
- Female
- Humans
- Indazoles
- Ipilimumab
- Kidney Neoplasms -- pathology
- Male
- Middle Aged
- Nivolumab
- Progression-Free Survival
- Protein Kinase Inhibitors -- therapeutic use
- Pyridines -- therapeutic use
- Pyrimidines -- therapeutic use
- Receptors, Vascular Endothelial Growth Factor -- antagonists & inhibitors
- Sulfonamides -- therapeutic use
- Sunitinib -- therapeutic use
- Treatment Failure
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.